HCW Biologics Inc. (NASDAQ: HCWB) reported its financial results for the three and nine months ended September 30, 2026, alongside updates on its clinical development pipeline. The company, which focuses on fusion immunotherapeutics for autoimmune diseases, cancer, and senescence, announced that revenues for the third quarter of 2026 were $55,463, compared to $15,606 in the prior year period. For the nine months ended September 30, 2026, total revenues reached $6.7 million.

Research and development expenses decreased to $1.2 million for the third quarter of 2026, down from $1.4 million in the prior year, and to $3.7 million for the nine-month period, down from $4.1 million. General and administrative expenses also declined to $1.4 million for the quarter and $5.1 million for the nine months. The company reported a net loss of $3.2 million for the third quarter of 2026 and $5.0 million for the first nine months of the year.

In terms of business development, HCW Biologics raised $8.6 million in equity financing during the nine months ended September 30, 2026. Additionally, on November 4, 2026, the company secured up to $10.0 million in debt financing, receiving $3.0 million at closing and access to an additional $7.0 million subject to conditions. The company noted that it has sufficient funding to reach the completion of the Phase 1 clinical trial for its alopecia areata candidate, HCW9302, and the determination of the Recommended Phase 2 Dose, which are expected in the first quarter of 2027.

Regarding clinical progress, the company activated an additional clinical site for the HCW9302 Phase 1 study. The company also presented data at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC2026) in Phoenix, Arizona. The presentation highlighted the company's second-generation, tetravalent immune checkpoint inhibitor, HCW11-040, which was recognized as one of the top 150 abstracts out of over 1,200 submissions. Furthermore, the company shared data on its T Cell Engager Program candidate, HCW11-018b, detailing its ability to convert immunological "cold" tumors into "hot" tumors.

The company stated that it intends to file an Investigational New Drug (IND) application for HCW11-018b in the first half of 2027, following guidance received from the U.S. Food and Drug Administration (FDA) during a Type B meeting. In preparation for this, HCW Biologics has initiated cGMP manufacturing of HCW11-018b and created a high-expression production cell line. The company also completed the closing of an exclusive, worldwide licensing agreement with Beijing Trimmune Biotech Co., Ltd. for the in vivo rights for HCW11-006.

HCW Biologics disclosed that as of September 30, 2026, it has substantial doubt regarding its ability to continue as a going concern for at least 12 months without additional funding. The company also confirmed that it maintains compliance with Nasdaq's continued listing requirements.